Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Shares Outstanding (2022 - 2025)

Historic Shares Outstanding for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $86.5 million.

  • Century Therapeutics' Shares Outstanding rose 208.33% to $86.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.5 million, marking a year-over-year increase of 208.33%. This contributed to the annual value of $85.8 million for FY2024, which is 4226.47% up from last year.
  • As of Q3 2025, Century Therapeutics' Shares Outstanding stood at $86.5 million, which was up 208.33% from $86.3 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Shares Outstanding ranged from a high of $86.5 million in Q3 2025 and a low of $57.6 million during Q1 2022
  • For the 4-year period, Century Therapeutics' Shares Outstanding averaged around $70.0 million, with its median value being $60.3 million (2023).
  • In the last 5 years, Century Therapeutics' Shares Outstanding surged by 4256.14% in 2024 and then surged by 208.33% in 2025.
  • Century Therapeutics' Shares Outstanding (Quarter) stood at $58.5 million in 2022, then increased by 3.18% to $60.3 million in 2023, then surged by 42.26% to $85.8 million in 2024, then grew by 0.81% to $86.5 million in 2025.
  • Its last three reported values are $86.5 million in Q3 2025, $86.3 million for Q2 2025, and $86.1 million during Q1 2025.